Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis

被引：5

作者：

Yarman, S. ^{[1
]}

Yalin, G. Y. ^{[1
]}

Dogansen, S. C. ^{[1
]}

Canbaz, B. ^{[1
]}

Tanrikulu, S. ^{[1
]}

Akyuz, F. ^{[2
]}

机构：

[1] Istanbul Univ, Istanbul Fac Med, Div Endocrinol & Metab Dis, Dept Internal Med, TR-34093 Istanbul, Turkey

[2] Istanbul Univ, Istanbul Fac Med, Div Gastroenterohepatol, Dept Internal Med, Istanbul, Turkey

来源：

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2016年 / 41卷 / 05期

关键词：

acromegaly; long-acting somatostatin analogs; ulcerative colitis; INFLAMMATORY-BOWEL-DISEASE; TUMOR SHRINKAGE; PRIMARY THERAPY; GASTROINTESTINAL-TRACT; CROHNS-DISEASE; GROWTH-HORMONE; SUBSTANCE-P; OCTREOTIDE; MANAGEMENT; RECEPTORS;

D O I：

10.1111/jcpt.12412

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

What is known and objectiveSomatostatin analogs control GH/IGF-1 excess in acromegaly. Somatostatin receptors also mediate the complex effects of somatostatin on the gastrointestinal tract and may be defensive in inflammatory bowel diseases, such as ulcerative colitis. We present a patient who showed good response to long-acting octreotide (OCT-LAR) treatment in terms of both acromegaly and ulcerative colitis (UC). Case summaryA 58-year-old female patient with diagnosis of acromegaly and ulcerative colitis was started on long-acting somatostatin treatment as a first-line treatment for acromegaly as she refused to undergo transsphenoidal surgery. During the follow-up period, a significant amelioration was also observed in the course of ulcerative colitis, and clinical remission of both diseases was achieved uneventfully. What is new and conclusionSomatostatin appears to be a promising candidate in the treatment of inflammatory bowel diseases.

引用

页码：559 / 562

页数：4

共 38 条

[11] Doherty GA, 2009, CLIN EXP GASTROENTER, V2, P139
[12] OCTREOTIDE EFFECTIVELY DECREASES MUCOSAL DAMAGE IN EXPERIMENTAL COLITIS
ELIAKIM, R
KARMELI, F
OKON, E
RACHMILEWITZ, D
[J]. GUT, 1993, 34 (02) : 264 - 269
[13] Inflammatory bowel disease: Etiology and pathogenesis
Fiocchi, C
[J]. GASTROENTEROLOGY, 1998, 115 (01) : 182 - 205
[14] Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
Freda, PU
Katznelson, L
van der Lely, AJ
Reyes, CM
Zhao, SH
Rabinowitz, D
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (08) : 4465 - 4473
[15] A Consensus on Criteria for Cure of Acromegaly
Giustina, A.
Chanson, P.
Bronstein, M. D.
Klibanski, A.
Lamberts, S.
Casanueva, F. F.
Trainer, P.
Ghigo, E.
Ho, K.
Melmed, S.
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (07) : 3141 - 3148
[16] SOMATOSTATIN ANALOGS SUPPRESS THE INFLAMMATORY REACTION IN-VIVO
KARALIS, K
MASTORAKOS, G
CHROUSOS, GP
TOLIS, G
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (05) : 2000 - 2006
[17] SOMATOSTATIN IN THE IDIOPATHIC INFLAMMATORY BOWEL DISEASES
KOCH, TR
CARNEY, JA
MORRIS, VA
GO, VLW
[J]. DISEASES OF THE COLON & RECTUM, 1988, 31 (03) : 198 - 203
[18] NEUROPEPTIDES AND INFLAMMATION - A SOMATOSTATIN ANALOG AS A SELECTIVE ANTAGONIST OF NEUTROPHIL ACTIVATION BY SUBSTANCE-P
KOLASINSKI, SL
HAINES, KA
SIEGEL, EL
CRONSTEIN, BN
ABRAMSON, SB
[J]. ARTHRITIS AND RHEUMATISM, 1992, 35 (04): : 369 - 375
[19] ALTERATIONS IN THE MUCOSAL IMMUNE-SYSTEM IN ULCERATIVE-COLITIS AND CROHNS-DISEASE
MACDERMOTT, RP
[J]. MEDICAL CLINICS OF NORTH AMERICA, 1994, 78 (06) : 1207 - 1231
[20] Manjila S, 2010, NEUROSURG FOCUS, V29, P4

← 1 2 3 4 →